

Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses

Juliette Ferlin, Rayan Farhat, Sandrine Belouzard, Laurence Cocquerel,

Antoine Bertin, Didier Hober, Jean Dubuisson, Yves Rouillé

▶ To cite this version:

Juliette Ferlin, Rayan Farhat, Sandrine Belouzard, Laurence Cocquerel, Antoine Bertin, et al.. Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses. Journal of General Virology, 2018, 99 (8), pp.1086-1096. 10.1099/jgv.0.001099 . hal-02113930

HAL Id: hal-02113930 https://hal.science/hal-02113930

Submitted on 29 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Title: Investigation of the role of GBF1 in the replication of positive-sense single-
2	stranded RNA viruses
3	
4	Authors: Juliette Ferlin ¹ , Rayan Farhat ^{1,*} , Sandrine Belouzard ¹ , Laurence Cocquerel ¹ ,
5	Antoine Bertin ² , Didier Hober ² , Jean Dubuisson ¹ and Yves Rouillé ¹
6	
7	Affiliations: ¹ Center for Infection & Immunity of Lille, Inserm U1019, CNRS UMR-8204,
8	Institut Pasteur de Lille, Université de Lille, Lille, France
9	² Université de Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie EA3610,
10	Lille, France
11	
12	Correspondence: Yves Rouillé, yves.rouille@ibl.cnrs.fr
13	
14	*present address: Inserm U1052, Cancer Research Center of Lyon (CRCL), Université de
15	Lyon (UCBL1), CNRS UMR-5286, Centre Léon Bérard, Lyon, France
16	
17	Keywords: ADP-ribosylation factor, hepatitis C virus, coxsackievirus B4, human coronavirus
18	229E, Sindbis virus, yellow fever virus
19	
20	Subject category: Animal viruses – positive-strand RNA
21	
22	Word counts: abstract: 223; body of text: 5047
23	

24 Abbreviations: Arf, ADP ribosylation factor; BFA, brefeldin A; BIG, brefeldin A-inhibited 25 guanine nucleotide-exchange protein for ADP ribosylation factor; CRISPR-Cas9, clustered 26 regularly interspaced short palindromic repeats-CRISPR associated protein 9; COP-I, coat 27 protein complex I; CVB4, coxsackievirus B4; DMEM, Dulbecco's modified Eagle's medium; 28 GBF1, golgi brefeldin A resistant guanine nucleotide exchange factor 1; GCA, golgicide A; 29 GEF, guanine nucleotide-exchange factor; HCV, hepatitis C virus; HCoV-229E, human 30 coronavirus 229E ; hpi, hour(s) post infection; KO, knockout; MTS, 3-(4,5-dimethylthiazol-31 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; SINV, Sindbis virus; 32 VLDL, very low density lipoprotein, YFV, yellow fever virus.

34 ABSTRACT

35 GBF1 has emerged as a host factor required for the replication of positive-sense single-36 stranded RNA viruses of different families, but its mechanism of action is still unknown. 37 GBF1 is a guanine-nucleotide exchange factor for Arf family members. Recently, we 38 identified Arf4 and Arf5 (class II Arfs), as host factors required for the replication of hepatitis 39 C virus (HCV), a GBF1-dependent virus. To assess if a GBF1/class II Arfs pathway is 40 conserved among positive-sense single-stranded RNA viruses, we investigated yellow fever virus (YFV), Sindbis virus (SINV), coxsackievirus B4 (CVB4) and human coronavirus 229E 41 42 (HCoV-229E). We found that GBF1 is involved in the replication of these viruses. However, 43 using siRNA or CRISPR-Cas9 technologies, the depletion of Arf1, Arf3, Arf4 or Arf5 had no 44 impact on viral replication. In contrast, the depletion of Arfs pairs suggested that class II Arfs 45 could be involved in HCoV-229E, YFV and SINV infection, as for HCV, but not in CVB4 46 infection. In addition, another Arf pair, Arf1 and Arf4, appears essential for YFV and SINV infection, but not for other viruses. Finally, CVB4 infection was not inhibited by any 47 48 combination of Arf depletion. We conclude that the mechanism of action of GBF1 in viral 49 replication appears not to be conserved, and that a subset of positive-sense single-stranded 50 RNA viruses from different families might require class II Arfs for their replication.

52 INTRODUCTION

53 Positive-sense, single-stranded RNA viruses ((+)RNA viruses) replicate their genome in the 54 cytoplasm of their host cell. Their RNA-dependent RNA polymerase and other non-structural 55 proteins implicated in the replication are found in association with cellular membranes. For a 56 number of (+)RNA viruses, intracellular membranes of the host cells are rearranged during 57 replication and viral replication complexes are associated with these membrane 58 rearrangements. The morphology and origin of these membrane rearrangements appear to 59 vary for different viruses. However, it is possible that some conserved cellular pathways are 60 redirected during the replication of different viruses for the formation and functioning of these 61 membranous replication complexes.

62 GBF1 has recently emerged as a host factor involved in the replication of (+]RNA viruses of 63 the Picornaviridae [1-3], Coronaviridae [4], Flaviviridae [5,6] and Hepeviridae [7] families. 64 GBF1 is a brefeldin A (BFA)-sensitive guanine nucleotide exchange factor (GEF) of Arf 65 family members [8]. Through Arf1 activation, it participates to the regulation of COP-I-66 dependent vesicular transport, phospholipid metabolism, actin cytoskeleton dynamics at the 67 Golgi, and lipid droplet metabolism [9,10]. GBF1 has 6 conserved domains [11]. Its Arf-GEF 68 activity is catalyzed by the Sec7 domain and is selective for class I Arfs (Arf1-3) and class II 69 Arfs (Arf4 and Arf5) [8,12]. The functions of the other conserved domains are less defined 70 [11,13].

Little is known about the mechanism of action of GBF1 in viral infections. Its Arf-GEF activity appears to be of special importance at the onset of the replication of different viruses [4-7]. Accordingly, GBF1 is temporally recruited to replication complexes at early times of poliovirus replication, but not later on [14]. However, its Arf-GEF activity is not required for the formation of replication complexes-associated membrane rearrangements [1,4,5], suggesting that GBF1 is rather involved in a post-formation step of membrane-associated

77 replication complexes. It has been proposed that GBF1 function in viral infections could be 78 related to the regulation of COP-I, a molecular machinery involved in intracellular transport, 79 which has also been reported to be required for the replication of several (+)RNA viruses [15-80 19]. GBF1 regulates COP-I vesicle formation by stimulating COP-I recruitment to Golgi 81 membranes through Arf1 activation in a BFA-sensitive manner [9,10]. By analogy, the BFA 82 sensitivity of viral replication has been viewed as an argument for Arf1 involvement. In 83 support to this hypothesis, Arf1 [20], or both Arf1 and Arf3 [3] are activated during 84 enterovirus infection, and siRNA-mediated depletion of Arf1 [4,21] or of both Arf1 and Arf3 85 [3] impairs the replication of diverse (+)RNA viruses. However, an experimental 86 demonstration of the existence of a GBF1-Arf1-COP-I pathway involved in viral replication 87 is still lacking. During poliovirus infection, GBF1 is transiently recruited to replication 88 complexes, but this recruitment is not coupled to COP-I recruitment [14]. Moreover, during 89 poliovirus replication, GBF1 function does not depend on its catalytic Sec7 domain and 90 therefore on its Arf-GEF activity [22], indicating a mechanism of action unrelated to Arf1 91 activation.

92 We previously showed that GBF1 is critical to the replication of hepatitis C virus (HCV) [5], 93 and that its Arf-GEF activity is essential for regulating HCV replication [23]. However, GBF1 94 function in HCV replication is not mediated by Arf1, and is distinct from its regulatory 95 functions of the cellular secretory pathway and of the morphology of the Golgi complex, two 96 cellular processes that are mediated by COP-I. We found that different pairs of Arf proteins 97 are involved in these two functions of GBF1. The Arf1/Arf4 pair is involved in the regulation 98 of the secretory pathway and the Arf4/Arf5 pair in the replication of HCV [23]. In this study 99 we compared the requirement of Arfs for the replication of a series of GBF1-dependent 100 (+)RNA viruses from different families.

102

103 **RESULTS**

104 **BFA** sensitivity of (+)RNA viruses

105 To probe for GBF1 dependency, we made use of BFA, which inhibits GBF1 and two related 106 Arf-GEFs, named BIG1 and BIG2. In addition to HCV, we selected viruses from different 107 families of (+)RNA viruses, namely yellow fever virus (YFV, Flaviviridae), human 108 coronavirus 229E (HCoV-229E, Coronaviridae), coxsackievirus B4 (CVB4, Picornaviridae), 109 and Sindbis virus (SINV, Togaviridae). We also included human adenovirus-5, a DNA virus, 110 as a negative control. Cells were infected in the presence of increasing doses of BFA. To 111 avoid cell toxicity, BFA treatment was restricted to 8 hours of contact, when the infection was 112 scored later than 8 hours post-infection (hpi) (adeno, HCoV-229E, YFV, HCV). As 113 previously shown [5], adenovirus was not inhibited by BFA. In contrast, all RNA viruses 114 tested were sensitive to treatment with 0.1 to 10 μ g/ml BFA in a dose-dependent manner (fig. 115 1a). However, the extent of inhibition was different between viruses. When comparing the 116 inhibition of infection at 1 μ g/ml BFA, CVB4 and HCoV-229E appeared the most sensitive 117 viruses (~99% inhibition) and SINV the least one (62% inhibition), HCV and YFV having 118 intermediate sensitivities (~97% and ~88% inhibition, respectively). It is noteworthy that this 119 difference of sensitivity between viruses is only visible in the amplitude of the inhibitory 120 response, but not in the range of inhibitory doses of BFA. For all viruses, the first inhibitory 121 dose was 0.1 μ g/ml. No inhibition could be observed with 0.01 μ g/ml BFA for any virus. 122 Such a similar range of inhibitory doses observed with all RNA viruses suggests a similar 123 mode of action of BFA against all these viruses.

An MTS assay was performed to quantify the impact of BFA toxicity on Huh-7 cells (fig. 1b).
Two protocols were used to assess different protocols of infection. The assay was performed
either after 6 hours of contact in the presence of BFA, or after 8 hours of contact followed by

127 22 hours without BFA. These two protocols correspond to the shortest (CVB4 and SINV) and 128 longest (HCV) infection periods used for quantifying BFA inhibition of viral infections. The 129 only experimental condition showing an inhibition of cell growth or metabolism was with 8 130 hours incubation with 10 µg/ml BFA, followed by 22 hours without BFA. However, the 131 decrease was not in the same proportion as viral infection inhibitions measured in the same 132 condition. With 1 μ g/ml BFA, the inhibition of cell growth was minimal (~20% decrease), 133 whereas the inhibition of viral infections was close to maximal. These results, together with 134 the absence of inhibition of adenovirus infection, indicate that the inhibition of (+)RNA 135 viruses infections could not be explained by BFA toxicity.

136

137 GBF1 dependency of (+)RNA viruses

138 Because GBF1 is not the only target of BFA, we also assessed the impact of BFA on viral 139 infections in R1 cells. R1 cells are Huh-7-derived cells that have a point mutation in one copy 140 of the GBF1 gene [24]. This mutation replaces the methionine residue 832 in the catalytic 141 Sec7 domain by a leucine, a substitution that dramatically decreases BFA binding to GBF1 142 [25]. Since the two other BFA-sensitive Arf-GEFs, BIG1 and BIG2, are not mutated in R1 143 cells, any effect of a BFA treatment can be attributed to the inhibition of BIG1 and/or BIG2, 144 but not of GBF1. Inversely, an action of BFA in Huh-7 cells that is not reproduced in R1 cells 145 indicates an involvement of GBF1. We infected R1 cells in the presence of BFA and 146 quantified infections as we did before in Huh-7 cells. A ~100 fold decrease of BFA sensitivity 147 of all viral infections was observed (fig. 2a). The only inhibitory dose was 10 μ g/ml, and its 148 impact on infections was similar to that observed with $0.1 \,\mu$ g/ml in Huh-7 cells. This shift in 149 BFA sensitivity between R1 and parental Huh-7 cells indicates an involvement of GBF1 in 150 viral infections.

151 To further assess the importance of GBF1 in the infection of BFA-sensitive RNA viruses, we 152 used golgicide A (GCA), which is a specific inhibitor of GBF1, with no action on other BFA 153 targets [26]. GCA inhibited all BFA-sensitive viruses (fig. 2b), confirming that the observed 154 inhibition of infection by BFA was only due to its action on GBF1. Again, CVB4 and HCoV-155 229E were the two most affected viruses. As for BFA treatments, a small decrease in cell 156 growth was also observed with an 8-hour treatment with GCA followed by 22 hours with no 157 inhibitor and, to a lesser extent, with a 6-hour treatment (fig. 2c). These results confirm the 158 implication of GBF1 in the infection of all RNA viruses tested in this study.

159 We next investigated which step of the viral life cycle is affected by GBF1 inhibition. GBF1 160 was previously shown to be involved in a post-entry step of the HCV life cycle [5]. CVB4 161 and HCoV-229E, the two viruses the most affected by BFA, were investigated. To test GBF1 162 involvement during virus entry, BFA was added to cells during virus contact and removed 163 post-entry. To test GBF1 involvement at a post-entry step, cells were infected in the absence 164 of BFA, and BFA was added during 6 hours after virus removal. For both viruses, the 165 infection was inhibited when BFA was present at the post-entry step, but much less affected 166 when BFA was present at the entry step (fig. 3). These results indicated that GBF1 is likely 167 involved in a post-entry step of the life cycle of these (+)RNA viruses.

168

169 Involvement of Arf family members in the infection of (+)RNA viruses

We next assessed if the requirement of GBF1 for (+)RNA virus infection translated into an involvement of Arfs. Arf proteins potentially regulated by GBF1 and sensitive to BFA and GCA, namely Arf1, Arf3, Arf4 and Arf5 (human cells have no Arf2), were depleted with pools of synthetic siRNAs. The extent and the specificity of depletion were evaluated using a set of antibodies specific for each Arf protein (fig. 4a). Each siRNA pool specifically depleted the targeted protein with minimal impact on the expression of other Arfs (fig. 4b), except for two effects: Arf4 was overexpressed in cells depleted of Arf1, and Arf3 expression was slightly reduced in cells depleted of Arf4 (fig. 4c). Arf4 overexpression in Arf1-depleted cells was previously detected at the mRNA level [23], suggesting that these two Arf proteins are functionally linked. Other variations of expression levels appeared non-significant.

180 When siRNA-treated cells were infected, an inhibition of infection of approximately 10-30% 181 was measured for all viruses and for all Arf proteins (fig. 4d), except for CVB4, which was 182 not impacted by Arf4 and by Arf5 depletions. The inhibition of HCoV-229E and HCV 183 infection imposed by Arf1, Arf4 and Arf5 siRNAs appeared significant, but most of the other 184 inhibitions were not. Such a moderate and non-specific inhibition of infection in cells 185 depleted of each Arf protein was previously observed with HCV [23]. When Huh-7 cells were 186 depleted of two Arf proteins simultaneously, two pairs of siRNA pools induced an inhibition 187 of infection larger than the ones observed with single depletions (fig. 4e). SINV and YFV 188 infections were inhibited by the depletion of Arf1 and Arf4 (80% and 92% inhibition, respectively). In addition, HCV, SINV and YFV infections were inhibited in cells 189 190 simultaneously depleted of Arf4 and Arf5 (61%, 70% and 54% inhibition, respectively). 191 HCoV-229E infection also appeared to be reduced in cells depleted of this pair of Arfs, but 192 the inhibition was less dramatic (43% inhibition). In addition, similar inhibitions were also 193 observed with other Arf pairs for this virus. These inhibitions of infection were not correlated 194 to a loss of viability of the cells (fig. 4f). It is noteworthy that CVB4 infection was not 195 strongly affected by any Arf pair depletion. This lack of inhibition was confirmed by 196 immunoblot analysis of VP1 expression (fig. 4g).

197 To confirm the results obtained using siRNAs, we used CRISPR-Cas9 technology to generate 198 knockout (KO) cells. One Arf4KO, one Arf5KO and three Arf1KO cell lines were generated. 199 To avoid biases resulting from the use of clones, we used the whole population of cells 200 transfected with CRISPR-Cas9 constructs in each case. A small amount of residual expression of targeted proteins of 0 to 20% was measured for each cell line (fig. 5a). This residual expression likely resulted from the presence of a small amount of cells expressing the targeted protein. No major impact on the expression of other Arfs was observed, except for a slight decrease in Arf5 expression in the Arf1KO cell line 1.3, which was not observed for the two other Arf1KO cell lines (fig. 5b).

ArfKO cell lines were infected with HCoV-229E, HCV, SINV or YFV, the four viruses impacted in siRNA experiments. The infections of these four viruses were marginally affected in the three Arf1KO cell lines. They were inhibited by 20-30% in the Arf5KO cell line 5.1. In the Arf4KO cell line 4.1, HCV infection was inhibited by 20% and the infections by HCoV-229E, SINV and YFV were inhibited by ~50% (fig. 5c). These results confirmed the lack of inhibition of HCV infection by any single Arf depletion, and revealed an importance of Arf4 in HCoV-229E, SINV and YFV infections that was not detected in siRNA experiments.

213 We next tried to generate double KO cell lines by transfecting Arf4 CRISPR-Cas9 constructs 214 in the Arf5KO cell line or Arf5 CRISPR-Cas9 constructs in the Arf4KO cell line. 215 Unfortunately, most cells died during the selection, and the few surviving cells turned out not 216 to be double KO (data not shown). This indicates that a permanent invalidation of both class 217 II Arf genes is lethal for Huh-7 cells. Therefore, we used siRNAs to transiently deplete Arf 218 proteins in ArfKO cell lines. Again, we observed a strong toxicity of siRNAs to Arf1 or to 219 Arf5 transfected in the Arf4KO cell line. On the other hand, Arf4 depletion by siRNA 220 transfection was also toxic in Arf1KO cells, but not in Arf5KO cells. An MTS assay 221 confirmed the absence of toxicity of Arf4 siRNA transfection in the Arf5KO cell line 5.1 (fig. 222 6a).

Therefore, we used this experimental setup (siRNA-mediated depletion of Arf4 in Arf5KO cells) to confirm the importance of the pair of class II Arfs in viral infections. As controls, we used a non-targeting siRNA, as for experiments in parental Huh-7 cells, and also the Arf5 siRNA pool, which should have no impact in Arf5KO cells. As a control cell line, we used a
cell line selected after transfection of a CRISPR-Cas9 construct expressing no guide RNA.
The depletion of Arf4 and Arf5 was confirmed by immunobloting (fig. 6b). Arf5 was
undetectable in cells transfected with Arf5 siRNA and in Arf5KO cells, and was not affected
by the depletion of Arf4 in control cells. Arf4 expression was reduced to ~30% in both cell
lines after transfection of Arf4 siRNA.

232 siRNA-transfected control and Arf5KO cells were infected with HCoV-229E, HCV, SINV 233 and YFV. As expected from results of previous double depletions by siRNA, HCoV-229E, 234 HCV and SINV infections were strongly inhibited (85%, 89% and 83% inhibition, 235 respectively) (fig. 6c). In contrast, YFV infection was less impacted (53% inhibition). In all 236 other conditions, viral infections were inhibited by less than 40%, except in Arf5KO cells 237 transfected with Arf5 siRNAs, which surprisingly displayed an inhibition of almost 50% of 238 HCV and SINV infections, likely resulting from off-target effects. All together, these results 239 confirmed the importance of class II Arfs for infection by HCV [23] and by HCoV-229E, 240 SINV and YFV, as previously observed with double siRNAs transfection-based experiments.

241

242 **DISCUSSION**

243 In this study, we investigated whether the function of class II Arfs is conserved in infections 244 of GBF1-dependent (+)RNA viruses. GBF1 has been reported to be required for the 245 replication of different viruses, but its function is still not understood. Recently, we found that 246 the function of GBF1 in HCV replication differs from its function in the early secretory 247 pathway [24]. Whereas the effect of GBF1 inhibition or depletion on the secretion of albumin 248 and VLDL and on the Golgi morphology is phenocopied by simultaneously depleting both 249 Arf1 and Arf4, the depletion of this pair of Arfs has no impact on HCV infection [23]. In 250 contrast, the impact of GBF1 inhibition or depletion on HCV replication is phenocopied by 251 the depletion of another pair of Arfs. HCV replication is specifically inhibited by 252 simultaneously depleting Arf4 and Arf5. Interestingly, the depletion of this pair of Arfs has 253 no impact on the secretion of albumin or VLDL. Cells depleted of Arf4 and Arf5 accumulate 254 enlarged lipid droplets, suggesting a function related to the regulation of lipid metabolism or, 255 at least, to the morphology of these organelles, which are known to depend on GBF1 for their 256 metabolism [9,10]. Therefore, different GBF1 functions appear to be mediated by different 257 pairs of Arfs. This is in line with a previous report that the depletion of different Arf pairs 258 results in different specific phenotypes on secretory and endosomal compartments [27], which 259 are collectively observed upon BFA treatment of the cells. All these observations suggest that 260 different pairs of Arfs could mediate the different cellular functions that are regulated by 261 GBF1, BIG1 and BIG2, the three BFA-sensitive Arf-GEFs.

262 The function of the class II Arf pair in virus infection appears to be partly conserved among 263 viruses from different families. Their simultaneous depletion inhibited infection by HCV, 264 HCoV-229E, SINV and YFV, but not by CVB4. Interestingly, all these viruses also depend 265 on GBF1 for their replication, suggesting the existence of a GBF1-Arf4/5 pathway 266 requirement for some but not all (+)RNA viruses. These inhibitions were also observed to 267 some extent with the Arf4KO but not the Arf5KO cell line, suggesting a major importance of 268 Arf4, which had not been observed with siRNA-mediated depletions of individual Arf 269 proteins.

We also tried to confirm the contribution of class II Arfs with double KO cells. Unfortunately, the double KO was not viable, when each single KO was, suggesting that class II Arfs collectively fulfil a vital function in Huh-7 cells. We also observed a great reduction of viability in Arf4KO cells transfected with Arf5 siRNA. Nevertheless, the siRNA-mediated depletion of Arf4 in Arf5KO cells turned out to be not toxic. This difference probably resulted from a less pronounced down-regulation imposed by Arf4 siRNA, than by Arf5

276 siRNA. Therefore, the transfection of Arf4 siRNA in Arf5KO cells probably resulted in 277 residual Arf4 expression levels compatible with cell survival. This allowed us to confirm the 278 inhibition of HCV, HCoV-229E, SINV and YFV infections in cells depleted of both class II 279 Arfs. Class II Arfs were previously reported to be implicated in the dengue virus life cycle, 280 and more precisely in the assembly/secretion step, but the replication step was not 281 investigated [28]. It would have been interesting to confirm that the depletion of class II Arfs 282 actually affects the replication step of the life cycle of HCoV-229E, SINV and YFV, as it 283 does for HCV [23]. Unfortunately, we do not have the tools to address this question. 284 Nevertheless, we have shown that GBF1 is implicated in HCV replication [5] and in a post-285 entry step of the life cycle of HCoV-229E and CVB4 (this study).

286 In addition to the Arf4/Arf5 pair, YFV and SINV were also sensitive to the simultaneous 287 depletion of Arf1 and Arf4. As this Arf pair is involved in the regulation of the secretory 288 pathway [23,27], this suggests an involvement of this pathway in the life cycle of these 289 viruses. Currently, we do not know which step of their life cycle is actually impacted by the 290 depletion of this Arf pair. An entry inhibition can be hypothesized, resulting from a default of 291 expression of specific receptors at the cell surface. Alternatively, we cannot rule out the 292 possibility of an inhibition of the replication step. The Arf1/Arf4 pair has been previously 293 reported to be involved in the localization of the capsid protein to lipid droplets in dengue 294 virus-infected cells [29].

In contrast, CVB4 infection was not inhibited in cells depleted of both Arf4 and Arf5, nor of any other Arf pair, although it was inhibited by BFA in a GBF1-dependent manner. This suggests that the function of GBF1 in CVB4 infection could be unrelated to its Arf-GEF activity. Previously, a study by Lanke et al. demonstrated the implication of GBF1, but could not find any implication of Arfs, in the replication of CVB3 [2]. A sec7-independent GBF1 function has also been reported for poliovirus infection [22]. In contrast, the replication of 301 enterovirus 71 has been reported to depend on the pair of class I Arfs, Arf1 and Arf3 [3]. 302 Further studies will be necessary to assess if CVB4, and more generally which other 303 enteroviruses use a Sec7-independent function of GBF1 and what is the mechanism of action. 304 In conclusion, this study confirms and extends the implication of class II Arfs in the infection 305 of different (+)RNA viruses. Cellular pathways specifically controlled by class II Arfs are 306 currently unknown. Arf4 has been proposed to be part of a Golgi stress-response pathway 307 [30]. This function of Arf4 requires GBF1, but is not linked to Arf5. Collectively, class II 308 Arfs are not involved in the regulation of the secretory pathway [23,27]. They fulfil a vital 309 function in Huh-7 cells, and they also appear to be involved in regulating the morphology of 310 lipid droplets. However, we still do not know whether these two functions are related to each 311 other. Future work is required to decipher pathways specifically regulated by class II Arfs and 312 to identify effectors implicated in these pathways, which could be interesting new targets for 313 developing antiviral therapies.

314

315

316 METHODS

Reagents. Dulbecco's modified Eagle's medium (DMEM), phosphate-buffered saline (PBS)
and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Life Technologies. Goat and
fetal calf sera (FCS) were from Eurobio. Golgicide A and Mowiol 4-88 were from
Calbiochem. Protease inhibitors cocktail (Complete) was from Roche. Other chemicals were
from Sigma.

Antibodies. Mouse anti-HCV E1 mAb A4 [31] and mouse anti-YFV E mAb 2D12 (anti-E,
ATCC CRL-1689) were produced in vitro by using a MiniPerm apparatus (Heraeus). Mouse
anti-enterovirus VP1 mAb (clone 5-D8/1) was from DAKO. Mouse anti-Arf1 mAb 1A9/5
was from Santa Cruz Biotechnology. Mouse anti-Arf3 mAb was from BD Biosciences.

Rabbit anti-human Arf4 mAb EPR12133B was from Abcam. Mouse anti-Arf5 mAb 1B4 was
from Abnova. Mouse anti-β-tubulin mAb TUB 2.1 was from Sigma. Mouse anti-GFP mAb
was from Roche. Peroxidase-conjugated secondary antibodies and cyanine 3-conjugated goat
anti-mouse IgG were from Jackson Immunoresearch.

330 *Cell culture*. Huh-7 [32] and R1 [24] cells were grown at 37°C in Dulbecco's modified 331 Eagle's medium (DMEM), high glucose modification, supplemented with glutamax-I and 332 10% FCS.

333 HCV. The virus JFH1-CSN6A4 used in this study was produced as previously described [5].

For infection assays, cells were infected for 2 hours at 37°C, and fixed with cold methanol at
30 hpi.

Adenovirus. A recombinant defective adenovirus expressing a green fluorescent protein
(GFP) was as previously described [24]. Cells were infected for 1 hour at 37°C, and fixed for
20 minutes with PFA 3% at 16 hpi.

339 *SINV.* A recombinant Sindbis virus expressing HCV E1 glycoprotein was as previously 340 described [33]. Cells were infected for 1 hour at 37°C, and fixed with cold methanol at 6 hpi.

341 *YFV.* Yellow fever virus strain 17D was obtained from Dr Philippe Desprès (Institut Pasteur
342 de Paris). Cells were infected for 1 hour at 37°C, and fixed with PFA 3% at 24 hpi.

343 *HCoV-229E*. A recombinant human coronavirus 229E expressing GFP [34] was provided by
344 Dr Volker Thiel (University of Bern, Swiss). Cells were infected for 1 hour at 37°C, and fixed
345 with PFA 3% at 12 hpi.

CVB4. Coxsackievirus B4 strain E2 (CVB4) was previously provided by Dr Ji-Won Yoon
(Julia McFarlane Diabetes Research Center, Calgary, Alberta, Canada). CVB4 suspensions
were prepared and titred as described [35]. Cells were infected for 1 hour at 37°C, and fixed
with cold methanol at 6 hpi.

350 Infection assays. Huh-7 cells grown on glass coverslips or in 96-well plates were incubated 351 at 37°C for 1 or 2 hours (depending on the virus) in the presence of the virus. For each virus, 352 the viral stocks were diluted so as to obtain 20 to 40% of infected cells in control conditions. 353 Cells were fixed at a time that allows for a clear detection of infected cells vs. non-infected 354 cells, and avoids the detection of reinfection events, thus limiting the analysis to a single 355 round of infection. Cells were fixed for 20 min with 3% PFA or for 1 min with cold methanol 356 at -20°C. Cells were then rinsed with PBS and processed for immunofluorescence as 357 previously described [36] using specific primary mouse antibodies to HCV E1 (for both HCV 358 and SINV), YFV E, GFP (for HCoV-229E) or VP1 (for CVB4) followed by a cyanine-3-359 conjugated goat anti-mouse IgG secondary antibody for the detection of infected cells. Nuclei 360 were stained with DAPI. Immunostained cells were observed with a Zeiss Axiophot 361 microscope equipped with a 10x-magnification objective. Fluorescent signals were collected 362 with a Coolsnap ES camera (Photometrix). For each well or coverslip, a series of images of 363 randomly picked areas were automatically recorded using the Metamorph software. Cells 364 labeled with anti-virus mAbs were counted as infected cells. The total number of cells was 365 obtained from DAPI-labeled nuclei. Infected cells and nuclei were automatically counted 366 using a macro written in the ImageJ software. Infections were scored as the ratio of infected 367 over total cells. Data are presented as the percentage of infection relative to the control 368 condition.

369 *Drug treatments.* BFA and GCA were dissolved in DMSO, aliquoted and kept at -20°C. For 370 infection assays with SINV and CVB4, cells were incubated with BFA or GCA at the 371 indicated concentrations during virus inoculation and up to 6 hpi. For infection assays with 372 HCV, YFV, adenovirus and HCoV-229E, cells were incubated with BFA or GCA at the 373 indicated concentrations during virus inoculation and up to 8 hpi. The medium was then 374 removed; the cells were rinsed twice with PBS and returned to a drug-free medium until the375 end of the assay. For each experiment, a control condition with DMSO was included.

RNA interference. RNA interference experiments were performed as previously described
[23]. siRNAs were obtained from Dharmacon. For Arf3, Arf4 and Arf5, pools of 4 siRNA
were used. For Arf1, a mix of 2 individual siRNAs (J-011580-05-0005 & J-011580-08-0005)
was used to avoid off-target effects resulting from the use of the pool of 4 siRNAs [23]. The
control siRNA was the non-targeting siRNA #1 (D-001810-01-20). Briefly, cells were
transfected with siRNAs at 20 nM using lipofectamine RNAi MAX (Life Technologies). The
cells were passed the day after and infected at 3 days post-transfection.

383 Generation of knock out cells. Arf genes were invalidated in Huh-7 cells using the CRISPR-384 Cas9 technology. Guide RNA sequences were selected with the help of the CRISPR design 385 tool at http://crispr.mit.edu/ and inserted into pX330-U6-Chimeric_BB-CBh-hSpCas9, a gift 386 from Feng Zhang (Addgene plasmid # 42230). Selected target sequences for sgRNA design 387 were CTTAAGCTTGTAGAGGATCG for Arf1.1, GATCCTCTACAAGCTTAAGC for 388 Arf1.2, ATCCTCTACAAGCTTAAGCT for Arf1.3, GGAGATAGTGAGGCCCATGG for 389 Arf4.1 and GAAGATCCGCGAAAAGAGCG for Arf5.1 KO cell lines. Constructs were 390 generated as described [37]. Sub-confluent Huh-7 cells grown in 6-well plates were 391 transfected with 1 μ g of CRISPR-Cas9 construct and 50 ng of pPuro using the TransIT-LT1 392 transfection reagent (Mirus). Two days later, transfected cells were selected with puromycin 393 at 5 μ g/ml during 4 days. The puromycin-containing medium was renewed every day. After 4 394 days of selection, almost all the cells from control transfections with no pPuro plasmid were 395 dead. Selected cells were then expanded in puromycin-free medium. The residual expression 396 of targeted protein was measured using immunoblotting.

Immunoblotting. Cells were rinsed 3 times with cold PBS, and lysed at 4°C for 20 min in a
buffer containing 50 mM TrisCl, pH 7.5, 100 mM NaCl, 2 mM EDTA, 1% Triton- X, 0.1%

399 SDS, 1 mM PMSF, and a mix of protease inhibitors. Insoluble material was removed by 400 centrifugation at 4°C. The protein content was determined using a bicinchoninic acid assay 401 (Sigma). The proteins were then resolved by SDS-PAGE and transferred onto nitrocellulose 402 membranes (Hybond-ECL; Amersham) using a Trans-Blot apparatus (Bio-Rad). Proteins of 403 interest were revealed with specific primary antibodies, followed by species-specific 404 secondary antibodies conjugated to peroxidase. Proteins were visualized using enhanced 405 chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate from Thermofischer 406 Scientific). The signals were recorded using a LAS 3000 apparatus (Fujifilm). Quantification 407 of unsaturated signals was carried out using the gel quantification function of ImageJ.

408 *Viability assay.* An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4409 sulfophenyl)-2H-tetrazolium]-based viability assay (CellTiter 96 aqueous nonradioactive cell
410 proliferation assay from Promega) was conducted as recommended by the manufacturer using
411 sub-confluent cell cultures grown in 96-well plates.

412 Statistical analysis. Statistical analysis was performed using the software Prism. The 413 significance between groups was determined by one-way ANOVA and a Dunnett post-hoc 414 test. Only significant p-values are indicated by the asterisks above the graphs.

415

416

417 AUTHOR STATEMENTS

Funding information: This work was supported in part by the French 'Agence Nationale de
Recherche sur le Sida et les hépatites virales' (ANRS). JF was supported by a pre-doctoral
fellowship from ANRS.

- 422 Acknowledgements: The authors thank Dr Philippe Desprès, Dr Volker Thiel and Dr Feng
- 423 Zhang for providing us with viruses and plasmid. Some data were generated with the help of
- 424 the imaging core facility of the Institut Pasteur de Lille (BICeL).
- **Conflicts of interest**: The authors declare that no conflict of interest exists

429 **REFERENCES**

- 430
- Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. A critical role of a
 cellular membrane traffic protein in poliovirus RNA replication. *PLoS Pathog*. 2008
 Nov 1;4:e1000216.
- 434
 434
 435
 435
 436
 Lanke KHW, van der Schaar HM, Belov GA, Feng Q, Duijsings D, *et al.* GBF1, a
 436
 436
 436
 436
 436
 437
 436
 438
 438
 439
 439
 439
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
 430
- 437 3. Wang J, Du J, Jin Q. Class I ADP-Ribosylation Factors Are Involved in Enterovirus
 438 71 Replication. Zheng Z-M, editor. *PLoS ONE*. 2014;9(6):e99768.
- 4. Verheije MH, Raaben M, Mari M, Lintelo te EG, Reggiori F, et al. Mouse hepatitis
 coronavirus RNA replication depends on GBF1-mediated ARF1 activation. *PLoS Pathog*. 2008;4:e1000088.
- 442 5. Goueslain L, Alsaleh K, Horellou P, Roingeard P, Descamps V, et al. Identification
 443 of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol.
 444 2010;84:773–787.
- 6. Carpp LN, Rogers RS, Moritz RL, Aitchison JD. Quantitative proteomic analysis of host-virus interactions reveals a role for Golgi brefeldin A resistance factor 1 (GBF1) in dengue infection. *Mol Cell Proteomics*. 2014;13:2836–2854.
- Farhat R, Ankavay M, Lebsir N, Gouttenoire J, Jackson CL, et al. Identification of
 GBF1 as a cellular factor required for hepatitis E virus RNA replication. *Cell Microbiol*. 2018;20:e12804.
- 8. Claude A, Zhao BP, Kuziemsky CE, Dahan S, Berger SJ, et al. GBF1: A novel
 Golgi-associated BFA-resistant guanine nucleotide exchange factor that displays
 specificity for ADP-ribosylation factor 5. J Cell Biol. 1999;146:71–84.
- 454 9. Donaldson JG, Jackson CL. ARF family G proteins and their regulators: roles in
 455 membrane transport, development and disease. *Nat Rev Mol Cell Biol*. 2011;12:362–
 456 375.
- Wright J, Kahn RA, Sztul E. Regulating the large Sec7 ARF guanine nucleotide
 exchange factors: the when, where and how of activation. *Cell Mol Life Sci.*2014;71:3419–3438.
- 460 11. Bui QT, Golinelli-Cohen M-P, Jackson CL. Large Arf1 guanine nucleotide exchange
 461 factors: evolution, domain structure, and roles in membrane trafficking and human
 462 disease. *Mol Genet Genomics*. 2009;282:329–350.
- 463 12. Szul T, Grabski R, Lyons S, Morohashi Y, Shestopal S, *et al.* Dissecting the role of
 464 the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and protein
 465 trafficking. *J Cell Sci.* 2007;120:3929–3940.
- 466 13. Bouvet S, Golinelli-Cohen M-P, Contremoulins V, Jackson CL. Targeting of the

- 467 Arf-GEF GBF1 to lipid droplets and Golgi membranes. *J Cell Sci.* 2013;126:4794–
 468 4805.
- 469 14. Richards AL, Soares-Martins JAP, Riddell GT, Jackson WT. Generation of unique poliovirus RNA replication organelles. *MBio*. 2014;5:e00833–13.
- 471 15. Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA. Differential requirements for
 472 COPI coats in formation of replication complexes among three genera of
 473 Picornaviridae. *J Virol.* 2002;76:11113–11122.
- 474 16. Cherry S, Kunte A, Wang H, Coyne C, Rawson RB *et al.* COPI activity coupled
 475 with fatty acid biosynthesis is required for viral replication. *PLoS Pathog*. 2006;2:e102.
- Tai AW, Benita Y, Peng LF, Kim S-S, Sakamoto N, et al. A Functional Genomic
 Screen Identifies Cellular Cofactors of Hepatitis C Virus Replication. *Cell Host Microbe*. 2009;5:298–307.
- 479 18. Wang J, Wu Z, Jin Q. COPI is required for enterovirus 71 replication. *PLoS ONE*.
 480 2012;7:e38035.
- 481 19. de Wilde AH, Wannee KF, Scholte FEM, Goeman JJ, Dijke ten P, et al. A
 482 Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host
 483 Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including
 484 Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway
 485 Proteins. J Virol. 2015;89:8318–8333.
- 486 20. Belov GA, Altan-Bonnet N, Kovtunovych G, Jackson CL, Lippincott-Schwartz J,
 487 *et al.* Hijacking components of the cellular secretory pathway for replication of
 488 poliovirus RNA. J Virol. 2007;81:558–567.
- 489 21. Matto M, Sklan EH, David N, Melamed-Book N, Casanova JE, et al. Role for ADP
 490 Ribosylation Factor 1 in the Regulation of Hepatitis C Virus Replication. J Virol.
 491 2011;85:946–956.
- 492 22. Belov GA, Kovtunovych G, Jackson CL, Ehrenfeld E. Poliovirus replication
 493 requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. *Cell*494 *Microbiol*. 2010;12:1463–1479.
- 495 23. Farhat R, Séron K, Ferlin J, Fénéant L, Belouzard S, *et al.* Identification of class II
 496 ADP-ribosylation factors as cellular factors required for hepatitis C virus replication.
 497 *Cell Microbiol.* 2016;18:1121–1133.
- 498 24. Farhat R, Goueslain L, Wychowski C, Belouzard S, Fénéant L, *et al.* Hepatitis C
 499 virus replication and Golgi function in brefeldin a-resistant hepatoma-derived cells.
 500 *PLoS ONE*. 2013;8:e74491.
- 501 25. Renault L, Guibert B, Cherfils J. Structural snapshots of the mechanism and
 502 inhibition of a guanine nucleotide exchange factor. *Nature*. 2003;426:525–530.
- 503 26. Sáenz JB, Sun WJ, Chang JW, Li J, Bursulaya B, et al. Golgicide A reveals
 504 essential roles for GBF1 in Golgi assembly and function. Nat Chem Biol. 2009;5:157–
 505 165.

- 506 27. Volpicelli-Daley LA, Li Y, Zhang C-J, Kahn RA. Isoform-selective effects of the
 507 depletion of ADP-ribosylation factors 1-5 on membrane traffic. *Mol Biol Cell*.
 508 2005;16:4495–4508.
- 509 28. Kudelko M, Brault J-B, Kwok K, Li MY, Pardigon N, et al. Class II ADP510 ribosylation factors are required for efficient secretion of dengue viruses. J Biol Chem.
 511 2012;287:767–777.
- 512 29. Iglesias NG, Mondotte JA, Byk LA, De Maio FA, Samsa MM, *et al.* Dengue Virus
 513 Uses a Non-Canonical Function of the Host GBF1-Arf-COPI System for Capsid
 514 Protein Accumulation on Lipid Droplets. *Traffic*. 2015;16:962–977.
- 30. Reiling JH, Olive AJ, Sanyal S, Carette JE, Brummelkamp TR, et al. A CREB3ARF4 signalling pathway mediates the response to Golgi stress and susceptibility to
 pathogens. *Nat Cell Biol*. 2013;15:1473–1485.
- 518 31. **Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG**, *et al.* Formation
 519 and intracellular localization of hepatitis C virus envelope glycoprotein complexes
 520 expressed by recombinant vaccinia and Sindbis viruses. *J Virol.* 1994;68:6147–6160.
- 32. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human
 hepatoma cells lines with differentiated functions in chemically defined medium. *Cancer Res.* 1982;42:3858–3863.
- 33. Duvet S, Chirat F, Mir AM, Verbert A, Dubuisson J, *et al.* Reciprocal relationship
 between alpha1,2 mannosidase processing and reglucosylation in the rough
 endoplasmic reticulum of Man-P-Dol deficient cells. *Eur J Biochem*. 2000;267:1146–
 1152.
- 528 34. Thiel V, Herold J, Schelle B, Siddell SG. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. *J Gen Virol*.
 530 2001;82:1273–1281.
- 531 35. Engelmann I, Alidjinou EK, Bertin A, Bossu J, Villenet C, *et al.* Persistent
 532 coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic
 533 cells. *Cell Mol Life Sci.* 2017;74:3851–3861.
- 36. Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, *et al.* Subcellular
 localization of hepatitis C virus structural proteins in a cell culture system that
 efficiently replicates the virus. *J Virol.* 2006;80:2832–2841.
- 537 37. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, *et al.* Genome engineering using
 538 the CRISPR-Cas9 system. *Nat Protoc*. 2013;8:2281–2308.
- 539
- 540

541 FIGURE LEGENDS

542 Figure 1. Brefeldin A sensitivity of viral infections. (a) Huh-7 cells were infected in the 543 presence of indicated BFA concentrations. Infections were quantified by immunofluorescence 544 assay and expressed as percentage of controls with no BFA. Error bars represent the standard 545 deviation for 3 independent experiments. (b) Huh-7 cells were incubated with indicated BFA 546 concentrations for 6h (BFA 6h) or for 8h followed by 22h without BFA (BFA 8h / DMEM 547 22h), and cell viability was assessed using an MTS assay. Error bars represent the standard 548 deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and 549 .001, respectively.

550

551 Figure 2. GBF1 requirement for viral infections. (a) R1 cells were infected in the presence 552 of indicated BFA concentrations. Infections were quantified by immunofluorescence assay 553 and expressed as percentage of controls with no BFA. Error bars represent the standard 554 deviation for 3 independent experiments. (b) Huh-7 cells were infected in the presence of 50 555 µM GCA or 0.1% DMSO. Infections were quantified by immunofluorescence assay and 556 expressed as percentage of DMSO controls. Error bars represent the standard deviation for 3 557 independent experiments. (c) Huh-7 cells were incubated with indicated GCA concentrations 558 for 6h (GCA 6h) or for 8h followed by 22h without GCA (GCA 8h / DMEM 22h), and cell 559 viability was assessed using an MTS assay. Error bars represent the standard deviation for 3 560 independent experiments. *, **, and *** mean p-values below .05, .01, and .001, respectively. 561

Figure 3. Brefeldin A inhibits a post-entry step. Huh-7 cells were infected in the presence of $1 \mu g/ml$ BFA or 0.02% DMSO during (entry) and/or after (post-entry) virus inoculation, as indicated. Infections were quantified by immunofluorescence assay and expressed as percentage of controls with no BFA. The data are the means of 2 independent experiments. 566

567 Figure 4. Impact of siRNA-mediated Arf depletion on viral infections. (a) Specificity of 568 anti-Arf mAbs probed on lysates of Huh-7 cells expressing the proteins indicated above the 569 blots. (b, c) Specificity of siRNA-mediated depletions. Huh-7 cells were transfected with 570 indicated siRNAs. Arf proteins expression was monitored by immunoblotting at 3 days post-571 transfection (b), and the bands were quantified (c). Results are expressed as percentages of 572 control non-targeting (siNT1) siRNA. Error bars represent the standard deviation for 3 573 independent experiments. (d, e) Huh-7 cells were transfected with indicated siRNAs (d) or 574 siRNA pairs (e) and infected at 3 days post-transfection. Infections were quantified by 575 immunofluorescence assay and expressed as percentage of control siNT1-transfected cells. 576 Error bars represent the standard deviation for 6 independent experiments. (f) Cell viability of 577 siRNA-transfected Huh-7 cells probed at 3 days post-transfection using an MTS assay and 578 expressed as a percentage of control siNT1-transfected cells. Error bars represent the standard 579 deviation for 3 independent experiments. *, **, and *** mean p-values below .05, .01, and 580 .001, respectively. (g) Huh-7 cells were transfected with indicated siRNA pairs and infected 581 with CVB4 at 3 days post-transfection. The expression of VP1, Arf proteins and tubulin was 582 monitored by immunoblotting.

583

Figure 5. Viral infections of ArfKO cell lines. Arf5KO (5.1), Arf4KO (4.1) and Arf1KO (1.1; 1.2 and 1.3) cell lines were generated using the CRISPR-Cas9 technology. A control cell line was generated with no sgRNA. (a, b) Arf proteins expression was monitored by immunoblotting (a) and the bands were quantified (b). Results are expressed as percentages relative to the control cell line. The data are the means of 2 independent experiments. (c) KO cells were infected with indicated viruses. Infection were quantified by immunofluorescence

assay and expressed as percentage of control KO cells. The data are the means of 2independent experiments.

592

593 Figure 6. Impact of siRNA-mediated Arf4 depletion in Arf5KO cells on viral infections. 594 Control and Arf5KO cell lines were transfected with siRNAs to Arf4 or Arf5 or control non-595 targeting siNT1. At 3 days post-transfection, (a) the cell viability was measured using an 596 MTS assay, (b) Arf4 and Arf5 expression was monitored by immunoblotting, and (c) the cells 597 were infected with indicated viruses. Infections were quantified by immunofluorescence assay 598 and expressed as percentage of control siRNA (NT1)-transfected control cells. Error bars 599 represent the standard deviation for 3 independent experiments. *, **, and *** mean p-values 600 below .05, .01, and .001, respectively.



Figure 1



Figure 2



Figure 3







Figure 5







